Epinephrine and Cortisol in Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

EARLY_PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-31

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates the effects of two hormones called epinephrine and cortisol on how the brain processes emotional material using functional MRI to measure brain activity. The study hopes to learn how epinephrine and cortisol affect the brain differently in depressed and non-depressed individuals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Brain Hippocampal Volume Relationship With Anxious Symptoms in Major Depressive Patients

NCT04430556

Major Depressive Disorder Anxiety Disorders

UNKNOWN NA

Effects of Anticipation of Pain Relief on Brain Mechanisms

NCT00200876

Pain

COMPLETED NA

Affective Processing in Depression and Epilepsy

NCT00855725

Epilepsy Depression Healthy

TERMINATED

Study of Brain Circuitry in Anxiety Disorders

NCT01849432

Posttraumatic Stress Disorder Panic Disorder Specific Phobias

COMPLETED

Neural Correlates of Stress Reduction

NCT01488422

Stress Psychological Stress Life Stress +2 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Arm, CORT + EPI, then PLB + EPI

Healthy participant will receive cortisol pill and epinephrine infusion

Group Type ACTIVE_COMPARATOR

Hydrocortisone Acetate (CORT)

Intervention Type DRUG

Participants will receive a single dose of hydrocortisone at a dosage of 0.65 mg/kg

Epinephrine Sulfate (EPI)

Intervention Type DRUG

Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min

Healthy Arm, PLB + EPI, then CORT + EPI

Healthy participant will receive placebo pill and epinephrine infusion

Group Type ACTIVE_COMPARATOR

Epinephrine Sulfate (EPI)

Intervention Type DRUG

Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min

Placebo (PLB)

Intervention Type DRUG

Participants will receive a placebo

Depression Arm, CORT + EPI, then PLB + EPI

Depressed participant will receive cortisol pill and epinephrine infusion

Group Type EXPERIMENTAL

Hydrocortisone Acetate (CORT)

Intervention Type DRUG

Participants will receive a single dose of hydrocortisone at a dosage of 0.65 mg/kg

Epinephrine Sulfate (EPI)

Intervention Type DRUG

Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min

Depression Arm, PLB + EPI, then CORT + EPI

Depressed participant will receive placebo pill and epinephrine infusion

Group Type EXPERIMENTAL

Epinephrine Sulfate (EPI)

Intervention Type DRUG

Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min

Placebo (PLB)

Intervention Type DRUG

Participants will receive a placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydrocortisone Acetate (CORT)

Participants will receive a single dose of hydrocortisone at a dosage of 0.65 mg/kg

Intervention Type DRUG

Epinephrine Sulfate (EPI)

Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min

Intervention Type DRUG

Placebo (PLB)

Participants will receive a placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cortef Adrenalin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Weight of less than 280 pounds
* HAM-D Score of greater than 7 for depression participants

Exclusion Criteria

* Psychotropic medications
* Recent surgery
* Endocrine disorders
* Liver disease
* Kidney disease
* Thyroid disorder
* History of malaria
* Tuberculosis
* Osteoporosis
* Glaucoma or cataracts
* Chronic expressed infections (herpes, HIV, etc)
* History of congestive heart failure
* History of recurring seizures
* Stomach ulcers
* Comorbid psychosis
* Current use of illicit drugs
* Diabetes
* Any cardiovascular disease (angina, hypovolemia, coronary artery disease, low/high blood pressure, etc)
* Any pulmonary disease
* Any cerebrovascular disease
* Sulfate hypersensitivity
* Glaucoma
* Infection
* Pregnancy
* Parkinson's Disease
* Panic Disorder
* Over 280 pounds in weight
* In-dwelling ferrous metals
* Left handed
* Abnormal hearing
* Claustrophobic
* Head injury with loss of consciousness
* Active suicidal ideation

Minimum Eligible Age

21 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes